• TaqI Restriction Endonuclease: Practical DNA Digestion

  2026-09-04

  TaqI provides rapid, sequence-specific cleavage for plasmid DNA, PCR products, and genomic DNA containing its recognition site, supporting cloning, mapping, and routine DNA manipulation. It is for scientific research use only and should not be used for diagnostic or medical procedures.

• Cediranib (AZD2171) In Vitro Workflow Guide

  2026-09-03

  Learn how to use Cediranib (AZD2171) to separate direct VEGFR signaling effects from delayed changes in proliferation and cell death. This practical workflow covers endothelial assays, phospho-Akt measurements, co-culture models, dosing, and troubleshooting for cancer research.

• Growth Arrest vs Cell Death in Cancer Drug Testing

  2026-09-03

  Hannah R. Schwartz’s dissertation, In Vitro Methods to Better Evaluate Drug Responses in Cancer, highlights a major interpretive problem in oncology assays: relative viability and fractional viability are related but non-equivalent measurements. Its findings support time-resolved, endpoint-specific workflows that distinguish proliferative arrest from true cell killing when evaluating therapeutic responses.

• Sulfachloropyridazine: Applied Research Workflows

  2026-09-02

  Sulfachloropyridazine connects target-level DHPS inhibition with antimicrobial susceptibility testing, microbiome profiling, and infection-model research. This practical guide covers solvent handling, assay design, combination studies, and troubleshooting informed by integrated cecal microbiome and metabolomics data.

• Allosteric Biosensor Tracks Endogenous Protein Dynamics

  2026-09-02

  The reference study introduces Step, an allosteric genetically encoded biosensor that converts binding of an endogenous protein to an aptamer into fluorescence through dual-locked fluorogenic RNA modules. Its circular circStep implementation enables live-cell visualization of native protein abundance, localization, and relocalization without directly tagging or overexpressing the protein of interest.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-09-01

  The reference preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also accelerate WIP1-mediated dephosphorylation by reshaping the kinase activation loop. Biochemical assays and crystal structures connect this dual action to exposure of the activation-loop phosphothreonine, offering a mechanistic framework for designing more selective kinase-directed interventions.

• Vancomycin hydrochloride: Assays, Workflows & Tips

  2026-09-01

  Use Vancomycin hydrochloride as a defined Gram-positive benchmark for susceptibility testing, selective culture workflows, resistance tracking, and translational infection studies. This guide connects practical assay setup with longitudinal PKPD concepts that reveal adaptive resistance beyond a single MIC value.

• Rotigotine: Workflow for PD Research

  2026-08-31

  Rotigotine is a dopamine D2/D3 receptor agonist for linking receptor pharmacology with neuroprotection, motor phenotyping, and depression-related behavioral assays. This workflow explains how to select exposure windows, separate antidepressant-like activity from locomotor stimulation, and troubleshoot formulation and route-specific variables.

• EPZ5676: DOT1L Inhibitor Workflow Guide

  2026-08-31

  EPZ5676 combines picomolar biochemical binding with strong selectivity for DOT1L, making it a focused tool for connecting H3K79 methylation to MLL-fusion leukemia biology. This guide translates that profile into enzyme assays, MV4-11 cell workflows, orthogonal epigenetic readouts, and practical troubleshooting.

• Mubritinib (TAK 165) for OXPHOS Assays

  2026-08-30

  Mubritinib (TAK 165) is a versatile research probe for separating mitochondrial complex I dependence from historical HER2 activity. This guide shows how to apply it in AML, PEL, and HER2-oriented assays while improving solubility control, endpoint selection, and mechanism validation.

• COX-2 Timing in Venom-Induced Muscle Repair

  2026-08-29

  A Microvascular Research study shows that COX-2 has a time-dependent role after Bothrops asper venom damages skeletal muscle microvasculature: its early activity helps limit ischemia, whereas early pathway inhibition later enhances proangiogenic remodeling. The findings position lumiracoxib as a mechanistic tool for studying how prostaglandin signaling coordinates vascular injury, ischemia, and revascularization.

• AZD8055 Protocol Guide for Dual mTOR Inhibition

  2026-08-28

  AZD8055 is a selective ATP-competitive mTOR inhibitor for preclinical studies requiring coordinated interrogation of mTORC1 and mTORC2 signaling. This guide focuses on solvent handling, assay design, pathway verification, and interpretation limits; it is not intended to support clinical efficacy claims or protocols requiring a water-soluble compound.

• Cediranib (AZD2171) for VEGFR Assays

  2026-08-28

  Use Cediranib (AZD2171) to separate VEGFR-driven signaling, angiogenic behavior, growth arrest, and cell killing in cancer research. This practical guide combines pathway pharmacology with assay-design principles that improve interpretation beyond a single viability endpoint.

• Mubritinib (TAK 165): From HER2 to Complex I

  2026-08-27

  Mubritinib is best understood not as a conventional HER2 inhibitor, but as a mechanistically distinctive mitochondrial complex I inhibitor with translational potential in oxidative phosphorylation-dependent malignancies. This thought-leadership analysis connects the compound’s toxicophore, selective activity in AML and PEL models, cardiac safety implications, and practical study-design priorities.

• Imatinib (STI571): From Kinase Tool to Translational Lens

  2026-08-27

  Imatinib (STI571) is more than a pathway inhibitor: it is a controlled perturbation tool for connecting Abl, PDGF receptor, and c-Kit signaling with disease phenotypes. This thought-leadership guide outlines how translational researchers can deploy it across kinase assays, CML models, and increasingly complex tumor systems.

8083 records 1/539 page Next 12345 下5页 Last page